A Research Study to See How Well an Eye Drop, SURF-200 (0.02% and 0.04% Betamethasone Sodium Phosphate), Works, What Side Effects There Are, and to Compare it With Vehicle (Placebo) in Subjects Diagnosed With Dry Eye Disease and Experiencing An Epis

• Status: Recruiting
• Trial end date: 2023-03-01

Summary

SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.

The purpose of this research study is to see how well SURF-200 works and what side effects there are, and to compare it with vehicle (placebo). The study will involve about 120 study participants at multiple research sites in the United States.

• Phase: Phase 2

Details

• Lead Sponsor: Surface Pharmaceuticals, Inc.
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate